Vaccines
26 February 2025
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate17 February 2025
LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA717 February 2025
Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY14 February 2025
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine4 February 2025
COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes28 January 2025
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting23 January 2025
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines23 December 2024
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines17 December 2024
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)16 December 2024
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India14 December 2024
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate14 December 2024
PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine at ESMO-IO 202410 December 2024
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza10 December 2024
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome10 December 2024
First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal COVID-19 Vaccine Candidate3 December 2024
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants28 November 2024
Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate22 November 2024
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans19 November 2024
Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine15 November 2024
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports